NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

慢性骨髓性白血病 (CML) 治療的全球市場:2021年∼2028年

Global Chronic Myelogenous Leukemia Treatment Market - 2021-2028

出版商 DataM Intelligence 商品編碼 1008532
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
慢性骨髓性白血病 (CML) 治療的全球市場:2021年∼2028年 Global Chronic Myelogenous Leukemia Treatment Market - 2021-2028
出版日期: 2021年06月01日內容資訊: 英文 180 Pages
簡介

慢性粒細胞白血病 (CML) 是一種始於骨髓的造血細胞並侵入血液的癌症。這一市場增長的一個主要驅動因素是越來越多的研究來確定慢性粒細胞白血病(CML)的病因,並且在預測期內慢性粒細胞白血病(CML)治療市場的增長有望提振。

本報告提供全球慢性骨髓性白血病 (CML) 治療市場相關調查分析,提供產業分析,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

目錄

第1章 全球慢性骨髓性白血病 (CML) 治療市場調查手法與調查範圍

第2章 全球慢性骨髓性白血病 (CML) 治療市場:市場定義與市場概要

第3章 全球慢性骨髓性白血病 (CML) 治療市場:摘要整理

第4章 全球慢性骨髓性白血病 (CML) 治療市場:市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球慢性骨髓性白血病 (CML) 治療市場:產業分析

  • 波特的五力分析
  • 流行病學分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球慢性骨髓性白血病 (CML) 治療市場:COVID-19分析

  • COVID-19對市場的影響分析
  • COVID-19的價格趨勢
  • 需求與供給的頻譜
  • 政府在COVID-19疫情下的市場相關措施
  • 製造商策略性舉措
  • 結論

第7章 全球慢性骨髓性白血病 (CML) 治療市場:藥物的各類型

  • 簡介
  • Bosulif (Bosutinib)
  • Gleevec (Imatinib)
  • Iclusig (Ponatinib)
  • Sprycel (Dasatinib)
  • Tasigna (Nilotinib)
  • Synribo (Omacetaxine Mepesuccinate)
  • Asciminib
  • 其他

第8章 全球慢性骨髓性白血病 (CML) 治療市場:治療的各類型

  • 簡介
  • 標靶治療
  • 化療
  • 生物學的療法
  • 其他

第9章 全球慢性骨髓性白血病 (CML) 治療市場:各終端用戶

  • 簡介
  • 醫院
  • 診所
  • 門診病人手術中心

第10章 全球慢性骨髓性白血病 (CML) 治療市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東·非洲

第11章 全球慢性骨髓性白血病 (CML) 治療市場:競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品基準
  • 值得注意的主要企業
  • 有顛覆性技術的企業
  • Start-Ups企業

第12章 全球慢性骨髓性白血病 (CML) 治療市場:企業簡介

  • Novartis AG
  • Bristol-Myers Squibb
  • Teva Pharmaceuticals Industries Ltd.
  • ARIAD Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Hospira, Inc.
  • CStone Pharma
  • JD Health
  • Jiangsu Hengrui Medicine Co., Ltd
  • Shanghai Junshi Biosciences Co., Ltd.等

第13章 全球慢性骨髓性白血病 (CML) 治療市場:DataM

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The global chronic myelogenous leukemia treatment market size was valued US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Chronic myeloid leukemia (CML) is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. This cancer majorly causes fatigue, fever, easy bleeding, infection, bone pain, anemia, and swollen spleen among the patients who are middle-aged people or older. However, it can occur in children also.

Market Dynamics

The major factors driving the growth of this market are the increasing number of researches that are carried out to identify the causes of CML cancer is expected to boost growth of the chronic myeloid leukemia treatment market over the forecast period.

Increasing prevalence of chronic myelogenous leukaemia (CML) will drive the market growth

The increasing prevalence of chronic myelogenous leukemia (CML) drives the market growth. According to the American Cancer Society's (ACS) publication of 2019, 15% of leukemia cases are of chronic myeloid leukemia. It is estimated that about 8,990 new cases will be diagnosed with CML in 2019, and about 1,140 people will die of CML.

This statistic shows a considerable number of people prone to suffer from chronic myeloid leukemia, which may directly impact the growth of the CML market. Furthermore, the growing investments in research and development programs by biotechnology and pharmaceutical companies also boost the market growth.

The presence of a robust domain for cancer treatment will drive market growth

The presence of a solid domain for cancer treatment is expected to improve the chances of market growth. The vendors operating in the global chronic myelogenous leukemia treatment have made concerted efforts to improve their revenue index. The relation of the global chronic myelogenous leukemia treatment market to the healthcare industry is crucial for market vendors. The established vendors have succeeded by tying up with leading medical institutes and healthcare facilities. Furthermore, research and development activities in niche areas have also improved the growth stakes of the leading vendors.

It is expected that the global chronic myelogenous leukemia treatment market would witness new mergers in the years to come. This projection is based on the quest of small vendors to turn lucrative by joining hands with large and established companies. Furthermore, the global chronic myelogenous leukemia treatment market is also expected to witness the entry of new vendors in the forecast period.

Complications related to chemotherapy and stringent regulations on drugs will hamper the market

However, the complications related to chemotherapy and stringent regulations on drugs are the two major drawbacks of the market's growth. Some chemo drugs cause long-term side effects, like heart or nerve damage or fertility problems. Sometimes the side effects can last a lifetime, such as when chemo causes long-term damage to the heart, lungs, kidneys, or reproductive organs. Certain types of chemo sometimes cause delayed effects, such as second cancer that may show up many years later.

Industry Analysis

PEST Analysis:

COVID-19 Impact Analysis

According to the CDC, the senior population with underlying severe therapeutic conditions, including people with chronic myelogenous leukemia, might be at higher risk for severe illness from COVID-19. According to a research article published in a famous Communications Journal in 2020, during the COVID-19 pandemic 2020, strict measures were implemented by the government to prevent the spread of COVID-19, which adversely affected the routine monitoring of chronic myelogenous leukemia disease. Therefore, these patients were considered in the emergency category during the pandemic. Besides, the increased sales of cancer products will foster healthy growth of the market amid COVID-19.

Segment Analysis

Bosulif (Bosutinib) segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

The bosulif are expected to account for the largest share of the market. The bosulif is a prescription medicine used to treat adults who have CML. The approval of bosulif in these patients was based on molecular and cytogenetic response rates. There is an ongoing clinical study to confirm clinical benefits. Bosutinib received US FDA and EU European Medicines Agency approval in September 2012 and March 2013, respectively, to treat disease. Females who can become pregnant should have a pregnancy test before starting treatment with bosulif and should use effective birth control (contraception) during treatment with bosulif and at least two weeks after the last dose.

Chemotherapy segment are expected to dominate the chronic myelogenous leukemia treatment market, by treatment type, during the forecast period

Chemotherapy is the use of anti-cancer medications used to treatment of cancerous cells. Chemotherapy has been done for many years and is one of the most prevalent cancer treatments. In most instances, chemotherapy works by preventing the cancer cell's ability to grow or multiply. Several groups of medications work in many ways to fight cancer cells. Chemotherapy may be used alone for some types of cancer or in sequence with other treatments such as radiation or surgery. Often, a mixture of chemotherapy drugs is used to fight particular cancer. Some chemotherapy drugs are given in a specific amount depending on the type of cancer used for treatment.

While chemotherapy can be quite efficient in treating specific cancers, chemotherapy medications reach all body parts. The carcinoma cells that cause may be many side effects during therapy.

Geographical Analysis

North America region holds the largest market share in the global chronic myelogenous leukemia treatment market

North America region is dominating the global CML treatment market accounted for the largest market share in 2020, owing to the growing incidence of CML in the region, established healthcare infrastructure, and availability of branded drugs are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in research partnerships are some drivers expected to increase the market growth. The United States holds the largest share of the market. The United States has a unique healthcare system among developed countries.

As per Cancer.net, about 10% of all leukemia are CML. In 2015, around 8,220 people (4,610 men and 3,610 women) in the United States were diagnosed with CML. Most of these were adults, with an average age of diagnosis at 64 years. It is estimated that 1,070 deaths (570 men and 500 women) occurred this year. The American Cancer Society estimates that in 2016, about 8,220 new cases will be diagnosed with CML (4,610 in men and 3,610 in women), and about 1,070 people will die of CML (570 men and 500 women). Thus, North America is expected to retain its domination in the forecast period.

Competitive Landscape

The chronic myelogenous leukemia treatment market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., ARIAD Pharmaceuticals, Inc., Pfizer, Inc., Hospira, Inc., CStone Pharma, JD Health, Jiangsu Hengrui Medicine Co., Ltd, Shanghai Junshi Biosciences Co., Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the chronic myelogenous leukemia treatment Market globally.

Chronic Myelogenous Leukemia Treatment Market Key Companies to Watch

Pfizer Inc.

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, and biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

Why Purchase the Report?

  • Visualize the composition of the chronic myelogenous leukemia treatment market segmentation by treatment type, drug type and end user highlighting the key commercial assets and players.
  • Identify commercial opportunities in chronic myelogenous leukemia treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of chronic myelogenous leukemia treatment market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global chronic myelogenous leukemia treatment Market report would provide an access to an approx. 61 market data table, 53 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Chronic Myelogenous Leukemia Treatment Market - By Treatment Type

  • Targeted therapy
  • Chemotherapy
  • Biologic therapy
  • Others

Global Chronic Myelogenous Leukemia Treatment Market - By Drug Type

  • Bosulif (Bosutinib)
  • Gleevec (Imatinib)
  • Iclusig (Ponatinib)
  • Sprycel (Dasatinib)
  • Tasigna (Nilotinib)
  • Synribo (Omacetaxine Mepesuccinate)
  • Asciminib
  • Others

Global Chronic Myelogenous Leukemia Treatment Market - By End User

  • Hospital
  • Clinics
  • Ambulatory Surgical Unit

Global Chronic Myelogenous Leukemia Treatment Market - By Region

  • North America
  • South America
  • Europe
  • Asia
  • Middle East & Africa

Table of Contents

1. Global Chronic Myelogenous Leukemia Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Chronic Myelogenous Leukemia Treatment Market - Market Definition and Overview

3. Global Chronic Myelogenous Leukemia Treatment Market - Executive Summary

  • 3.1. Market Snippet by Treatment Type
  • 3.2. Market Snippet by Drug Type
  • 3.3. Market Snippet by End User
  • 3.4. Market Snippet by Region

4. Global Chronic Myelogenous Leukemia Treatment Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of chronic myelogenous leukaemia (CML) will drive the market growth
      • 4.1.1.2. The presence of a robust domain for cancer treatment will drive market growth
    • 4.1.2. Restraints:
      • 4.1.2.1. Complications related to chemotherapy and stringent regulations on drugs will hamper the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Chronic Myelogenous Leukemia Treatment Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Global Chronic Myelogenous Leukemia Treatment Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Chronic Myelogenous Leukemia Treatment Market - By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 7.1.2. Market Attractiveness Index, By Surgical Devices Segment
  • 7.2. Bosulif (Bosutinib)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Gleevec (Imatinib)
  • 7.4. Iclusig (Ponatinib)
  • 7.5. Sprycel (Dasatinib)
  • 7.6. Tasigna (Nilotinib)
  • 7.7. Synribo (Omacetaxine Mepesuccinate)
  • 7.8. Asciminib
  • 7.9. Others

8. Global Chronic Myelogenous Leukemia Treatment Market - By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Targeted therapy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Chemotherapy
  • 8.4. Biologic therapy
  • 8.5. Others

9. Global Chronic Myelogenous Leukemia Treatment Market - By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Clinics
  • 9.4. Ambulatory Surgical Centers

10. Global Chronic Myelogenous Leukemia Treatment Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Types
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Chronic Myelogenous Leukemia Treatment Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch
  • 11.5. Company with disruptive technology
  • 11.6. Start Up Companies

12. Global Chronic Myelogenous Leukemia Treatment Market - Company Profiles

  • 12.1. Novartis AG*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bristol-Myers Squibb
  • 12.3. Teva Pharmaceuticals Industries Ltd.
  • 12.4. ARIAD Pharmaceuticals, Inc.
  • 12.5. Pfizer, Inc.
  • 12.6. Hospira, Inc.
  • 12.7. CStone Pharma
  • 12.8. JD Health
  • 12.9. Jiangsu Hengrui Medicine Co., Ltd
  • 12.10. Shanghai Junshi Biosciences Co., Ltd.

LIST NOT EXHAUSTIVE

13. Global Chronic Myelogenous Leukemia Treatment Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us